Clinical trial · no report yet · Phase 2
ABBY
ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
- NCT04523857 ↗
- Recruiting
- Abramson Cancer Center at Penn Medicine
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 27 | |
| YouTube | 1 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Pilot Trial of ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer Patients ("ABBY")
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Breast Cancer
- Interventions
- Abemaciclib; Hydroxychloroquine
- Arms
- A (Abema) · Experimental
- B (Abema + HCQ) · Experimental
- Enrollment
- 44 (estimated)
- Primary outcomes
- Incidence of treatment-emergent adverse events during cycle 1 of the safety cohort (safety of combination HCQ + Abema)
- Change in bone marrow DTC number evaluated by DTC-IHC assay after 6 cycles of therapy compared to baseline (Efficacy of Abema +/- HCQ in eliminating bone marrow DTCs)
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Start
- Nov 1, 2021
- Primary completion
- Dec 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04523857 · updated May 26, 2026